Picture of Verastem logo

VSTM — Verastem News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Verastem Inc expected to post a loss of 95 cents a share - Earnings Preview

* Verastem Inc  VSTM.OQ   VSTM.O  is expected to show a rise
in
quarterly revenue when it reports  results on August 6
(estimated) for the period ending June 30 2024
    * The Cambridge Massachusetts-based  company is expected to
report
revenue of $50 thousand, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Verastem Inc is for a
loss
of 95 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Verastem
Inc is
$17.50​, above​ its last closing price of $2.43. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -1.03       -1.00      -1.26     Missed  -26.4
 Dec. 31 2024  -0.74       -0.62      -1.02     Missed  -64.5
 Sep. 30 2023  -0.87       -0.84      -0.75     Beat    11​
 Jun. 30 2023  -1.07       -1.06      -1.37     Missed  -29.2
 ​​Mar.        -0.96       -0.98      -0.96     Beat    2.4
 31 2023                                                
 Dec. 31 2022  -1.20       -1.18      -0.96     Beat    18.4​
 Jan. 1 0001   -1.46       -1.46      -1.08     Beat    26
 Jun. 30 2022  -1.32       -1.32      -1.44     Missed  -9.1
 This summary was machine generated August 2 at 12:52 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Verastem

See all news